(Q39195618)

9 September 2017

title

Rapamycin increases pCREB, Bcl-2, and VEGF-A through ERK under normoxia (English)

1 reference

9 September 2017

1 reference

Yudong Liu

1

1 reference

9 September 2017

Qixin Zheng

2

1 reference

9 September 2017

Hongbin Wu

3

1 reference

9 September 2017

Xiaodong Guo

4

1 reference

9 September 2017

Jingfeng Li

5

1 reference

9 September 2017

Shaofei Hao

6

1 reference

9 September 2017

publication date

11 February 2013

1 reference

Acta Biochimica et Biophysica Sinica

9 September 2017

published in

1 reference

9 September 2017

volume

45

1 reference

9 September 2017

issue

4

1 reference

9 September 2017

page(s)

259-267

1 reference

Biology and therapeutic advances for pediatric osteosarcoma

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Retracted: Rapamycin Inhibits Proliferation of Hemangioma Endothelial Cells by Reducing HIF-1-Dependent Expression of VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

An emerging role for TOR signaling in mammalian tissue and stem cell physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

TOR regulation of AGC kinases in yeast and mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Calcium/calmodulin-dependent protein kinase IV limits organ damage in hepatic ischemia-reperfusion injury through induction of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Mammalian target of rapamycin inhibition in macrophages of asymptomatic HIV+ persons reverses the decrease in TLR-4-mediated TNF-α release through prolongation of MAPK pathway activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

CREB--a real culprit in oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Roles and regulation of the transcription factor CREB in pancreatic β -cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Insulin regulates GLUT1-mediated glucose transport in MG-63 human osteosarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

AKT plays a central role in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Cross-talk between PKA and Akt protects endothelial cells from apoptosis in the late ischemic preconditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

MEK/ERK signaling contributes to the maintenance of human embryonic stem cell self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

ERK1/2 MAP kinases in cell survival and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Oroxylin A increases BDNF production by activation of MAPK-CREB pathway in rat primary cortical neuronal culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

The rapamycin-sensitive phosphoproteome reveals that TOR controls protein kinase A toward some but not all substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Physiological substrates of cAMP-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/Akt pathway in differentiating intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMT002

21 January 2018

Identifiers

DOI

10.1093/ABBS/GMT002

1 reference

9 September 2017

1 reference